SANUWAVE HEALTH REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A

SANUWAVE HEALTH REPORTS FIRST QUARTER FINANCIAL

AND PROVIDES A BUSINESS UPDATE

SUWANEE, GA, May 16, 2018 SANUWAVE Health, Inc. (OTCQB:

SNWV) reported financial

results for the three months ended March 31, 2018 with the SEC on

Tuesday, May 15, 2018 and will provide a business update on a

conference call today, May 16, 2018 at 9:00 a.m. Eastern

for the first quarter of 2018 was $344,272 up 130% from the first

Shipped first US dermaPACE

Entered into an exclusive agreement for purchase

and sale of dermaPACE

Systems to certain governmental

healthcare facilities with Premier Shockwave Wound Care, Inc. and

Premier Shockwave, Inc. The contract includes a minimum purchase of

100 units over 3 years.

into a Master Equipment Lease with NFS Leasing Inc. to provide

financing for equipment placements.

Dr. Perry Mayer, Medical Director and principal at The Mayer

Institute TMI in Hamilton, Ontario, Canada to the

science advisory board.

at EWMA, CAET and Wounds Canada Spring conferences in May 2018 and

SAWC (Symposium of Advanced Wound Care) in April 2018.

With the FDA clearance, we have begun to develop and implement a

platform for rolling out the dermaPACE

System for treating DFU's in the

US. We are taking a methodical approach to the roll out to ensure

we will ultimately achieve our goal - The delivery of a

System to any location in the US that

will be treating DFU's.

Recap of SANUWAVE Attendance at Four Global Wound Care

is excited to recap the worldwide participation and unprecedented

user interest over the past three weeks at four significant global

wound care conferences. SANUWAVE executives were able to

divide and conquer around

the globe to ensure the display of the dermaPACE

System at all four critical exhibitions.

are elated and humbled by the outpouring of interest, support for

System, stated Kevin A. Richardson II, Chief Executive

Officer of SANUWAVE. SANUWAVE met with hundreds of doctors,

nurses and global healthcare professionals while receiving over

four hundred leads for interest in device leasing, ownership and

continued clinical study work. Our global objective of Healing

Today, Curing Tomorrow may yield results sooner than we

4 conferences in attendance:

2018 SAWC (Symposium on Advanced Wound

Care) Conference in Charlotte, NC on April 25 29. In

addition to the exhibitor's session, SANUWAVE was selected to

present the dermaPACE

System at the new product showcase.

2018 CAET (Canadian Association for

Enterostomal Therapy) 37th National Conference Educational Program

Turn Knowledge into Action on May 3 6, 2018

in Victoria, British Columbia. In addition to the exhibitor's

session, SANUWAVE was selected for the Shockwaves used for Disruption of

Biofilm poster presentation.

2018 EWMA (European Wound Management

Association) Conference in Krakow, Poland on May 9 -

2018 Wounds Canada Spring Conference

Sharing Solutions, Shaping the Future on May

11 12, 2018 at the RBC Convention Centre in Winnipeg,

this year, SANUWAVE looks forward to attending other major

conferences and the growing interest in the product. We plan to be

at SAWC in Las Vegas, NV on November 2-4 and the Wounds Canada Fall

conference in London on November 8-11.

First Quarter Financial Results

for the three months ended March 31, 2018 were $344,272, compared

to $149,569 for the same period in 2017, an increase of $194,703,

or 130%. Revenues resulted primarily from sales in the United

States and Europe of our dermaPACE

devices and related applicators. The increase in revenues for 2018

was due to first sale of dermaPACE

devices and applicators in the United States after obtaining FDA

approval and slight increase in refurbishment applicator

expenses for the three months ended March 31, 2018 were $1,300,066,

compared to $718,064 for the prior period, an increase of

$582,002. Research and development expenses increased by $89,106,

as a result of hiring of a full-time software engineer, accrual of

bonus for 2018 and a grant given to a university for clinical work

to be performed. General and

administrative expenses increased by $497,000, due to hiring of a

human resources director, higher travel costs, accrual of bonus for

2018, recruiting fees for open positions, higher legal and

accounting fees related to SEC filings and higher consultant fees

related to the commercialization of dermaPACE .

Net loss for the three months ended March 31, 2018 was $5,856,655,

or ($0.04) per share, compared with a net loss of $493,532, or

($0.00) per share for the same period in 2017, which is an increase

in the net loss of $5,363,123. The increase in the net loss for

2018 was a result of higher interest expense related to convertible

promissory notes, an increased loss on warrant valuation, and

increase in operating expenses discussed above.

March 31, 2018, the Company has cash and cash equivalents of

$154,205 compared to $730,184 as of December 31, 2017, a decrease

of $575,979. For the three months ended March 31, 2018 and 2017,

net cash used by operating activities was $1,848,553 and $114,884

respectively, primarily consisting of compensation costs, research

and development activities and general corporate operations. The

increase in the use of cash for operating activities for the three

months ended March 31, 2018, as compared to the same period for

2017, of $1,733,669 was primarily due to the increased operating